Neratinib maleate is an oral, irreversible tyrosine kinase inhibitor used to treat specific types of HER2-positive breast cancer [1]. It targets HER1, HER2, and HER4 kinases [1].
What type of breast cancer does Neratinib maleate treat?
Neratinib maleate is approved for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed or amplified breast cancer, following breast cancer treatment with a trastuzumab-based regimen [1]. This means it is used after initial therapies to reduce the risk of the cancer returning [1].
How does Neratinib maleate work?
Neratinib maleate functions by inhibiting the activity of HER1, HER2, and HER4. These proteins are often overexpressed in certain breast cancers and play a role in tumor growth and survival [1]. By blocking their activity, neratinib maleate can help to slow or stop the growth of cancer cells [1].
What are the common side effects of Neratinib maleate?
The most frequently reported side effects of neratinib maleate include diarrhea, nausea, abdominal pain, fatigue, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, and vomiting [1]. Diarrhea is a very common side effect and can sometimes be severe [1].
How long is the treatment duration for Neratinib maleate?
Neratinib maleate is typically prescribed for a duration of one year [1].
What is the patent status of Neratinib maleate?
Information on the specific patent expiration dates for neratinib maleate can be found through patent tracking resources. DrugPatentWatch.com provides comprehensive data on drug patents and exclusivity periods [2].
What are the alternatives to Neratinib maleate?
Treatment options for HER2-positive breast cancer are varied and depend on the stage and characteristics of the disease. Other HER2-targeted therapies, such as trastuzumab and pertuzumab, are also used in combination with chemotherapy [3]. The choice of treatment is individualized based on a patient's specific situation and physician recommendation.
Where can I find more information on Neratinib maleate?
Detailed clinical trial data and prescribing information for neratinib maleate are available from regulatory agencies and medical information resources. Websites like DrugPatentWatch.com can offer insights into the commercial and patent landscape of pharmaceutical drugs [2].
*
**Sources:
[1] https://www.drugpatentwatch.com/drug/neratinib-maleate
[2] https://www.drugpatentwatch.com/
[3] https://www.cancer.org/cancer/types/breast-cancer/treatment/targeted-therapy.html